A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Elapegademase-Lvlr (Revcovi)

First FDA approval2018-10-05
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$62.6M in CY2024 Part D spend150 claims · — beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
319 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Elapegademase-Lvlr used for?

Elapegademase-Lvlr is a this drug class medication tracked in Medicare Part D.

Is there a generic for Elapegademase-Lvlr?

No. Elapegademase-Lvlr is brand-only with no generic equivalents currently in market.

How much does my plan pay for Elapegademase-Lvlr?

NADAC pricing data not currently available for this drug.

Is Elapegademase-Lvlr on the FDA shortage list?

No. Elapegademase-Lvlr is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.